Drug & intervention
olaparib
RxCUI 1597582
RxNorm ingredient and formulation relationships
Source-verified product relationships. Every strength, delivery form and RxCUI remains a separate clinical concept.
Loading RxNorm relationships…
Clinical trials
40 shownPhase 1 Study of a Self-amplifying RNA Vaccine (ITI-5000) in Stage 2-3 Triple Negative Breast CancerNCT07652242 · 2026-07-14
RECRUITINGCirtuvivint/Olaparib in Breast Cancer Susceptibility Gene/Homologous Recombination Deficiency Platinum Resistant Ovarian CancerNCT06856499 · 2025-12-08
RECRUITINGA Clinical Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) in People With Breast Cancer (MK-2870-032)NCT06966700 · 2025-06-30
RECRUITINGStudy of Patritumab Deruxtecan Plus Pembrolizumab With Other Anticancer Agents in Participants With High-Risk Early-Stage Triple-Negative or Hormone Receptor-Low Positive/HER-2 Negative Breast Cancer (MK-1022-010, HERTHENA-Breast-03)NCT06797635 · 2025-03-20
RECRUITINGEvaluating the Addition of Elacestrant (Oral SERD) to Olaparib (PARP-inhibitor) in Patients With Advanced/Metastatic HR+/HER2- Breast CancerNCT06201234 · 2024-12-13
RECRUITINGPhase Ib Study of Axatilimab in Combination With Olaparib in BRCA1/2 and PALB2- Associated Metastatic HER2-negative Breast CancerNCT06488378 · 2024-08-13
RECRUITINGStudy of Orally Administered MOMA-313 in Participants With Advanced or Metastatic Solid TumorsNCT06545942 · 2024-08-13
RECRUITINGNovel Neoadjuvant and Adjuvant Strategy for Germline BRCA 1/2 Mutated Triple Negative Breast CancerNCT05485766 · 2024-07-16
RECRUITINGEstradiol Plus Olaparib for Breast Cancer (PHOEBE)NCT05900895 · 2024-07-15
RECRUITINGSubstudy 01A: Safety and Efficacy of Opevesostat (MK-5684)-Based Treatment Combinations or Opevesostat Alone in Participants With Metastatic Castration-resistant Prostate Cancer (mCRPC) (MK-5684-01A)NCT06353386 · 2024-05-20
RECRUITINGPET Dynamics to Response-Adapted Neoadjuvant Therapy in TNBCNCT06245889 · 2024-05-01
RECRUITINGSafety and Tolerability of LDRT+Sugemalimab+Chemotherapy+Olaparib for First-Line Treatment of SLFN-11 Positive ES-SCLCNCT06217757 · 2024-04-18
RECRUITINGA Phase 1 Study of XL309 (ISM3091) Alone and in Combination in Participants With Advanced Solid TumorsNCT05932862 · 2024-04-03
RECRUITINGDose-Expansion Modular Study To Explore the Safety, Tolerability, and Anti-tumor Activity of HER3- DXd Monotherapy and Combinations in Patients With Inoperable Advanced Breast Cancer (ABC) After Progression on T-DXdNCT06298084 · 2024-03-21
RECRUITINGPembro With Radiation With or Without OlaparibNCT05568550 · 2023-07-27
RECRUITINGStudy of ART6043 in Advanced/Metastatic Solid Tumors Patients (POLKA)NCT05898399 · 2023-06-30
RECRUITINGGenomics Guided Targeted Post-neoadjuvant Therapy in Patients With Early Breast Cancer (COGNITION-GUIDE)NCT05332561 · 2023-06-29
RECRUITINGTargeted Therapy Directed by Genetic Testing in Treating Patients With Locally Advanced or Advanced Solid Tumors, The ComboMATCH Screening TrialNCT05564377 · 2023-04-07
RECRUITINGClinical Outcomes of Use of Olaparib in Castration Resistant Prostate CancerNCT06783127 · 2023-01-01
RECRUITINGEvaluating the Efficacy and Safety of Fulvestrant Plus DNA Damage Repair Inhibitors After a CDK4/6 InhibitorNCT05536128 · 2022-12-31
RECRUITINGA Study of Radiation Therapy With Pembrolizumab and Olaparib or Other Radiosensitizers in Women Who Have Triple-Negative or Hormone-Receptor Positive/Her2 Negative Breast CancerNCT04683679 · 2021-04-21
RECRUITINGOlaparib in Patients With HRD Malignant MesotheliomaNCT04515836 · 2021-02-19
RECRUITINGOlaparib With Cediranib or AZD6738 for the Treatment of Advanced or Metastatic Germline BRCA Mutated Breast CancerNCT04090567 · 2020-07-28
RECRUITINGPHOENIX DDR/Anti-PD-L1 Trial: A Pre-surgical Window of Opportunity and Post-surgical Adjuvant Biomarker Study of DNA Damage Response Inhibition With or Without Anti-PD-L1 Immunotherapy in Patients With Neoadjuvant Treatment Resistant Residual Triple Negative Breast CancerNCT03740893 · 2019-10-15
RECRUITINGCarboplatin or Olaparib for BRcA Deficient Prostate CancerNCT04038502 · 2019-10-01
RECRUITINGPlatinum and Polyadenosine 5'Diphosphoribose Polymerisation Inhibitor for Neoadjuvant Treatment of Triple Negative Breast Cancer and/or Germline BRCA Positive Breast CancerNCT03150576 · 2016-05-01
RECRUITINGOlaparib in the Treatment of BRCA1/2 Unmutated and BRCA1 Promoter Methylated Recurrent and Metastatic Triple-negative Breast CancerNCT05522491 · 2026-09-01
NOT_YET_RECRUITINGA Study of BL-B01D1 Combination Therapy in Patients With Metastatic Castration-resistant Prostate CancerNCT07641855 · 2026-09-01
NOT_YET_RECRUITINGTemozolomide Monotherapy or in Combination With Olaparib in Patients With Triple Negative Breast Cancer (TNBC)NCT05128734 · 2026-04-01
NOT_YET_RECRUITINGFPI-2265 (225Ac-PSMA-I&T) and Olaparib for Patients With Metastatic Castration-Resistant Prostate Cancer (mCRPC)NCT06909825 · 2025-02-26
ACTIVE_NOT_RECRUITINGMaintenance Durvalumab (MEDI4736) and Olaparib (AZD2281) After Standard 1st Line Treatment (Carboplatin/Cisplatin, Etoposide, Durvalumab) in HRD Positive Extensive Disease (ED) Small-cell Lung Cancer (SCLC)NCT06419179 · 2024-10-09
ENROLLING_BY_INVITATIONOPTI - DOSE: Optimal Dosing of Oral Anticancer Drugs in Older AdultsNCT05949424 · 2024-05-01
UNKNOWNTesting the Addition of Immunotherapy With Hu5F9-G4 (Magrolimab) to the Usual PARP Inhibitor, Olaparib for Treatment of Metastatic or Recurrent Breast or Castrate-Resistant Prostate Cancer With BRCA MutationsNCT05807126 · 2024-03-05
WITHDRAWNChemo-free BRCA-targeted Neoadjuvant StrategyNCT05209529 · 2024-02-01
WITHDRAWNPhase Ib Trial of the KRAS G12C Inhibitor Adagrasib (MRTX849) in Combination With the PARP Inhibitor Olaparib in Patients With KRAS G12C Mutated Advanced Solid Tumors, With a Focus on Gynecological, Breast, Pancreatic and KEAP1 Mutated Non-small Cell Lung CancersNCT06130254 · 2024-01-30
TERMINATEDStudy to Evaluate TNG348 Alone and With a PARP Inhibitor in Patients With BRCA 1/2 Mutant or HRD+ Solid TumorsNCT06065059 · 2023-12-08
TERMINATEDA Phase III Randomised Study to Evaluate Dato-DXd and Durvalumab for Neoadjuvant/Adjuvant Treatment of Triple-Negative or Hormone Receptor-low/HER2-negative Breast CancerNCT06112379 · 2023-11-14
ACTIVE_NOT_RECRUITINGOlaparib and Alpelisib for Treatment of Metastatic Breast Cancer, A ComboMATCH Treatment TrialNCT05967286 · 2023-10-23
WITHDRAWNPhase II Study of PARP Inhibitor Olaparib and IV Ascorbate in Castration Resistant Prostate CancerNCT05501548 · 2023-06-30
TERMINATEDStudy of LP-184 in Patients With Advanced Solid TumorsNCT05933265 · 2023-06-09
ACTIVE_NOT_RECRUITINGConditions being studied
Breast Cancer23Prostate Cancer14Metastatic Castration-Resistant Prostate Cancer11Anatomic Stage IV Breast Cancer AJCC v89Metastatic Breast Cancer8Ovarian Cancer8BRCA1 Mutation7Triple Negative Breast Cancer7Advanced Malignant Solid Neoplasm6Advanced Solid Tumor6BRCA2 Mutation6Breast Neoplasms6Castration-Resistant Prostate Carcinoma6Advanced Breast Cancer5Anatomic Stage III Breast Cancer AJCC v85Metastatic Malignant Solid Neoplasm5Triple-Negative Breast Carcinoma5Recurrent Breast Carcinoma4Triple Negative Breast Neoplasms4Breast Cancer Metastatic3
Research locations
New YorkNew York, United States29HoustonTexas, United States27BostonMassachusetts, United States26MadridSpain25PhiladelphiaPennsylvania, United States25BaltimoreMaryland, United States24SeoulSouth Korea24BarcelonaSpain23NashvilleTennessee, United States22ChicagoIllinois, United States21DetroitMichigan, United States21Los AngelesCalifornia, United States17
Leading sponsors
AstraZeneca20National Cancer Institute (NCI)17Merck Sharp & Dohme LLC9M.D. Anderson Cancer Center7University of Washington4Institute of Cancer Research, United Kingdom3Memorial Sloan Kettering Cancer Center3OHSU Knight Cancer Institute3Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins3UNICANCER3Cambridge University Hospitals NHS Foundation Trust2Dana-Farber Cancer Institute2Gustave Roussy, Cancer Campus, Grand Paris2Laval University2Samsung Medical Center2
Drug identity and terminology: RxNorm. Trial relationships: ClinicalTrials.gov.